search

Active clinical trials for "Squamous Cell Carcinoma of Head and Neck"

Results 261-270 of 1255

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line...

Oral Cavity Squamous Cell Carcinoma

This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy based of cisplatin with sintilimab as first-line therapy for patients with advanced oral cavity squamous cell carcinoma.

Recruiting22 enrollment criteria

The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With...

Head and Neck Squamous Cell Carcinoma

This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of de-escalation of postoperative radiotherapy in locally advanced head and neck squamous cell carcinoma with pathological complete response/major pathological response to neoadjuvant therapy. The eligible patients are scheduled to administered postoperative radiotherapy, PTV 50Gy/25F, instead of the standard dose of 60Gy. The overall primary study hypothesis is that reducing the dose of postoperative radiotherapy in the specific population does not affect DFS but significantly reduces treatment related adverse events.

Recruiting28 enrollment criteria

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Cutaneous Squamous Cell CarcinomaSCC - Squamous Cell Carcinoma17 more

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Recruiting54 enrollment criteria

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated...

Head and Neck CancerHead and Neck Squamous Cell Carcinoma3 more

The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment. Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib. Afterwards, they will return to the clinic for follow up every 4 months for 2 years, every 6 month for the next 2 years, and then once a year for the rest of their life.

Recruiting47 enrollment criteria

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Non Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma10 more

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: Find the recommended dose of IMT-009 that can be safely given to participants Learn more about the side effects of IMT-009 Learn more about pharmacokinetics of IMT-009 Learn more about the effectiveness of IMT-009 Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009

Recruiting51 enrollment criteria

A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients...

CarcinomaNon-Small-Cell Lung13 more

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with tislelizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

Recruiting16 enrollment criteria

Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell...

Locally Advanced Head and Neck Squamous Cell Carcinoma

The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Cemiplimab is FDA approved for treatment of basal cell and squamous cell carcinoma of the skin as well as non-small cell lung cancer but not for squamous cell carcinoma of head and neck.

Recruiting37 enrollment criteria

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC...

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 200 patients are expected to be enrolled.

Recruiting61 enrollment criteria

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced...

CarcinomaNon-Small-Cell Lung4 more

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

Recruiting22 enrollment criteria

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally...

Squamous Cell Carcinoma of the Head and Neck

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.

Recruiting38 enrollment criteria
1...262728...126

Need Help? Contact our team!


We'll reach out to this number within 24 hrs